Agreed. But my comment was made in response to jbog's statement that PFE "could they buy teva ($10b sales) and use a model similar to novartis to put its own products generic but still control the channel somewhat."
I was just pointing out that like Novartis, Pfizer has a wholly-owned generic subsidiary they could - and do - use to put its own products generic.
But if the stand alone generic firms ceased to exist, you an be sure that none of these generic subsidiaries of big pharma would open up markets to generics.
Market Data 
Markets 
AI
